A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension
A Long-Term, Open-Label Study To Evaluate The Safety Of Sitaxsentan Sodium Treatment In Patients With Pulmonary Arterial Hypertension
This is a multi-center, open-label study of sitaxsentan sodium 100 mg taken orally once daily by subjects with PAH until sitaxsentan, in a particular country or region, is commercially available for the treatment of PAH or the study is closed.
Open-label extension
Inclusion Criteria:
Exclusion Criteria:
Torrence, California 90502, United States
Capital Federal, Buenos Aires C1416ASA, Argentina
Capital Federal, C1039AAO, Argentina
Chermside Q, Queensland 4032, Australia
Tel-Hashomer, Ramat Gan, 52601, Israel